Active	Status	Sponsor type	Region	Phase	Filter
9 Active 10 Inactive 19 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   - « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Arvat, Emanuela
LIBRETTO-531, NCT04211337 / 2019-001978-28: A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer	Active, not recruiting	3	291	Europe, Canada, Japan, US, RoW	Selpercatinib, LY3527723, LOXO-292, Cabozantinib, Vandetanib	Loxo Oncology, Inc., Eli Lilly and Company	Medullary Thyroid Cancer	05/23	02/26
Fonio, Paolo
BIOPEARL-ONE, NCT05911633: BioPearl™ Microspheres Loaded With Doxorubicin for the Treatment of Unresectable Hepatocellular Carcinoma (HCC)	Suspended	N/A	50	Europe	BioPearl™	Terumo Europe N.V.	Hepatocellular Carcinoma Non-resectable	06/26	11/27
Grosso, Marco
MioPain, NCT05204667 / 2021-000067-68: Different Dosage Regimens of Methocarbamol/Paracetamol in Acute Non-specific Low Back Pain. Study	Terminated	4	172	Europe	380 mg/300 mg comprimidos metocarbamol/paracetamol - 4 times daily, Robaxisal compuesto, 380 mg/300 mg comprimidos metocarbamol/paracetamol - 6 times daily	Aziende Chimiche Riunite Angelini Francesco S.p.A, Hippocrates Research	Low Back Pain	11/23	02/24
Tibaldi, Stefano
No trials found
Capello, Simona
No trials found
Sardo, Patrizia
No trials found
Berzovini, Claudio
No trials found
Santinelli, Francesca
No trials found
Calandri, Marco
No trials found
Ferraris, Andrea
No trials found

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Arvat, Emanuela
LIBRETTO-531, NCT04211337 / 2019-001978-28: A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer	Active, not recruiting	3	291	Europe, Canada, Japan, US, RoW	Selpercatinib, LY3527723, LOXO-292, Cabozantinib, Vandetanib	Loxo Oncology, Inc., Eli Lilly and Company	Medullary Thyroid Cancer	05/23	02/26
Fonio, Paolo
BIOPEARL-ONE, NCT05911633: BioPearl™ Microspheres Loaded With Doxorubicin for the Treatment of Unresectable Hepatocellular Carcinoma (HCC)	Suspended	N/A	50	Europe	BioPearl™	Terumo Europe N.V.	Hepatocellular Carcinoma Non-resectable	06/26	11/27
Grosso, Marco
MioPain, NCT05204667 / 2021-000067-68: Different Dosage Regimens of Methocarbamol/Paracetamol in Acute Non-specific Low Back Pain. Study	Terminated	4	172	Europe	380 mg/300 mg comprimidos metocarbamol/paracetamol - 4 times daily, Robaxisal compuesto, 380 mg/300 mg comprimidos metocarbamol/paracetamol - 6 times daily	Aziende Chimiche Riunite Angelini Francesco S.p.A, Hippocrates Research	Low Back Pain	11/23	02/24
Tibaldi, Stefano
No trials found
Capello, Simona
No trials found
Sardo, Patrizia
No trials found
Berzovini, Claudio
No trials found
Santinelli, Francesca
No trials found
Calandri, Marco
No trials found
Ferraris, Andrea
No trials found